Connection

Roberto Caporali to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Roberto Caporali has written about Antibodies, Monoclonal, Humanized.
Roberto Caporali
Connection Strength
0.568
Antibodies, Monoclonal, Humanized
  1. Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial. Clin Rheumatol. 2019 Mar; 38(3):841-849.
    View in: PubMed
    Score: 0.161
  2. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study. Clin Exp Rheumatol. 2017 Nov-Dec; 35(6):919-928.
    View in: PubMed
    Score: 0.145
  3. Patterns of tocilizumab use, effectiveness and safety in patients with rheumatoid arthritis: core data results from a set of multinational observational studies. Clin Exp Rheumatol. 2017 Nov-Dec; 35(6):899-906.
    View in: PubMed
    Score: 0.144
  4. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020 08; 16(8):465-470.
    View in: PubMed
    Score: 0.045
  5. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology (Oxford). 2018 03 01; 57(3):499-507.
    View in: PubMed
    Score: 0.038
  6. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. Clin Rheumatol. 2017 Apr; 36(4):753-761.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.